학술논문
A COMPARATIVE STUDY OF TAZOBACTAM/PIPERACILLIN AND PIPERACILLIN IN BACTERIAL PNEUMONIA / 細菌性肺炎に対するTazobactam/PiperacillinとPiperacillinの薬効比較試験成績
Document Type
Journal Article
Author
AKIHIRO HORI; AKIHISA SHINDO; AKIHO OHARA; AKIRA OHISHI; AKIRA SAITO; AKIRA WATANABE; ATSUHIKO SATO; ATSUHISA TAMURA; ATSUSHI SAITO; ATSUSHI TAKAHASHI; FUMIO MATSUMOTO; FUMIYUKI KUZE; HARUHITO HIRANO; HARUMI SHISHIDO; HIDEKAZU HANAKI; HIDEKI IKEDA; HIDEO GONDA; HIROFUMI KATAYAMA; HIROFUMI TANAKA; HIROKI TSUKADA; HIROKO ARIOKA; HIRONOBU KOGA; HIROSHI FUKUHARA; HIROSHI INOUE; HIROSHI SUGIMOTO; ISOKO OWAN; JINGORO SHIMADA; JUN GOTO; JUN INADOME; KANZO SUZUKI; KAORU SHIMADA; KATSUHIKO FURUUMI; KAZUHIRO OKUNO; KAZUKI KONISHI; KAZUNORI OISHI; KAZUNORI SHIMOGUCHI; KAZUO KITAGAWA; KAZUO SATO; KAZUO TAKEBE; KAZUSHIGE TSUYUGUCHI; KAZUYA HIGASHINO; KEIICHI MIKASA; KEIZO MATSUMOTO; KENICHI TAKEUCHI; KENJI BANDO; KENJI HASEGAWA; KENZO TAKAGI; KIYOSHI KONNO; KIYOYASU FUKUSHIMA; KOHEI HARA; KOHJI MURABAYASHI; KOHTARO KANEKO; KOICHI DEGUCHI; KOICHIRO KUDO; KOICHIRO NAKADA; KOJIRO YASUNAGA; KOTARO OIZUMI; KUNIHARU SHIDA; KUNIO SIRATO; MAKOTO KAWAKAMI; MAKOTO KIMURA; MAMORU OHTOMO; MASAAKI ARAKAWA; MASAHIDE TAKII; MASAHIKO YOSHIMOTO; MASAHIRO SAKAMOTO; MASAHIRO TAKAMOTO; MASANORI HIGUCHI; MASAO KAWAHARA; MASARU KOYAMA; MASARU NASU; MASATO TOHNO; MASAYOSHI SAWAKI; MASAYUKI ANDO; MASAZUMI SAISHO; MASUMI TOMIZAWA; MICHIO YAMAKIDO; MIKIO FUJISHITA; MITSUO OBANA; MORITAKA SUGA; MOTOO BABA; NAOHIKO TYONABAYASHI; NAOKI SAITA; NOBUHIRO NARITA; NOBUKI AOKI; NOBUYA OGAWA; NORIHISA AKIYAMA; OSAMU KURIMURA; OSAMU MORIYA; RIEKO KANAN; RINZO SOEJIMA; SABURO IZUMI; SAKURA KATOH; SEIBUN YONEZU; SHIGEKI ODAGIRI; SHIGEYUKI HOSHINO; SHINICHIRO OHYAMA; SHINZO KAWAGUCHI; SHOHEI KUSAKA; SHOICHIRO IRIMAJIRI; SUSUMU HARADA; SUSUMU YOSHIDA; TADAKAZU HATTORI; TADASHI ISHIDA; TAIJI MASUYAMA; TAKAO KOIKE; TAKAOKI OHYAMA; TAKASHI MOHRI; TAKASHI NAKANO; TAKASHI OGURA; TAKAYOSI OHNO; TAKEHIKO HIRAMOTO; TAKEO IMAI; TAKUYA SUZUKI; TASUKU SAKAMOTO; TATSUO NAKATANI; TETSUYA NISHIGAKI; TOHRU YAMASAKI; TOSHIHARU MATSUSHIMA; TOSHIHIKO TAKEUCHI; TOSHIHIRO MORITO; TOSHIHIRO NUKIWA; TOSHINOBU YAMAMOTO; TOSHIYUKI YAMAMOTO; TOYOKAZU TAMURA; TSUNEO ISHIBASHI; TSUNEO SAYAMA; TSUYOSHI NAGATAKE; YASUKO HARADA; YASUNOBU NODA; YASUO ARAI; YASUO MATSUOKA; YASUO ONO; YASUO TANNO; YASUO YAMADA; YASUYUKI SANO; YOSHIAKI RI; YOSHIHIRO HIRAI; YOSHIHITO NIKI; YOSHIKI ANAZAWA; YOSHIRO MOCHIZUKI; YOSHITAKA YAMANAKA; YOSHIYUKI ANZAI; YOSHIYUKI MITUTAKE; YUMIKO GOTO; YUTAKA NAKANO; 三笠 桂一; 下口 和矩; 中田 紘一郎; 中谷 龍王; 中野 孝司; 中野 豊; 丹野 恭夫; 久世 文幸; 二木 芳人; 井上 洋西; 今井 健郎; 今野 淳; 佐山 恒夫; 佐藤 和男; 佐藤 篤彦; 佐野 靖之; 光武 良幸; 入交 昭一郎; 出口 浩一; 副島 林造; 加藤 さくら; 北川 和生; 原 耕平; 原田 泰子; 原田 進; 古海 勝彦; 古賀 宏延; 吉本 正彦; 吉田 進; 坂本 正寛; 坂本 翊; 坂東 憲司; 堀 彰宏; 塚田 弘樹; 増山 泰治; 大友 守; 大山 眞一郎; 大山 高興; 大泉 耕太郎; 大湾 勤子; 大石 和徳; 大石 明; 大野 高義; 奥野 一裕; 守屋 修; 安永 幸二郎; 安藤 正幸; 安西 吉行; 宍戸 春美; 富沢 磨須美; 小倉 高志; 小原 秋穂; 小山 優; 小川 暢也; 小池 隆夫; 小田切 繁樹; 小花 光夫; 小西 一樹; 小野 康夫; 山中 吉隆; 山崎 透; 山木戸 道郎; 山本 俊信; 山本 俊幸; 山田 保夫; 島田 馨; 嶋田 甚五郎; 川上 誠; 川原 正士; 川口 信三; 工藤 宏一郎; 平居 義裕; 平本 雄彦; 平野 春人; 後藤 由美子; 後藤 純; 志田 國治; 成田 亘啓; 斉藤 厚; 日下 昌平; 星野 重幸; 普久原 浩; 最所 正純; 有岡 宏子; 服部 忠和; 望月 吉郎; 木村 丹; 杉本 浩史; 李 嘉明; 村林 晃二; 東野 一彌; 松岡 康夫; 松島 敏春; 松本 慶蔵; 松本 文夫; 栗村 統; 森戸 俊博; 樋口 雅則; 権田 秀雄; 武内 俊彦; 武内 健一; 武部 和夫; 毛利 孝; 永武 毅; 池田 英樹; 河南 里江子; 泉 三郎; 渡辺 彰; 澤木 政好; 瀧井 昌英; 片山 弘文; 田中 宏史; 田村 厚久; 田村 豊一; 白土 邦男; 石橋 凡雄; 石田 直; 福島 喜代康; 秋山 法久; 税田 直樹; 稲留 潤; 穴沢 予識; 米津 精文; 花木 英和; 荒井 康男; 荒川 正昭; 菅 守隆; 藤下 幹夫; 蝶名林 直彦; 西垣 哲哉; 貫和 敏博; 進藤 彰久; 遠野 正人; 那須 勝; 野田 康信; 金子 光太郎; 鈴木 幹三; 鈴木 沢耶; 長谷川 健司; 露口 一成; 青木 信樹; 馬場 基男; 高木 健三; 高本 正祇; 高橋 篤; 齋藤 玲
Source
The Japanese Journal of Antibiotics. 1995, 48(4):449
Subject
Language
Japanese
ISSN
0368-2781
2186-5477
2186-5477
Abstract
The efficacy, safety and usefulness of tazobactam/piperacillin (TAZ/PIPC), in bacterial pneumonia and lung abscess were determined with PIPC as the control in a multi-institutional comparative study a penicillin antibiotic for injection prepared by combining a newly developed β-lactamase inhibitor, tazobactam (TAZ), with a broad spectrum penicillin antibiotic, piperacillin (PIPC), at a ratio of 1: 4.TAZ/PIPC was intravenously injected at a dose of 2.5 g (titer) twice a day, and PIPC at a dose of 2.0 g (titer) twice a day as a rule for 14 days.The following results were obtained:1. The efficacy rates for bacterial pneumonia and lung abscess were 94% (80/85) in TAZ/PIPC group and 89% (70/79) in PIPC group, showing no significant difference between the twogroups.2. In a comparison of degrees of improvement in clinical symptoms, signs and laboratory findings, there were no significant differences between the two groups except for results on thoracic rales after three days of administration.3. As for bacteriological effects, the elimination rates of causative organisms were 98% (40/41) in the TAZ/PIPC group and 80% (28/35) in the PIPC group. Thus, the TAZ/PIPC group was significantly superior to the PIPC group. The TAZ/PIPC group showed significantly better eradication of bacateria as well. Bacteria considered to be pyogenic were detected in 80 patients (43 administered TAZ/PIPC and 37 administered PIPC), but β-lactamase production was confirmed in only 11 patients of each group. There were no significant differences in bacteriological effects among these patients. Minimum inhibitory concentrations of TAZ/PIPC against β-lactamase producing organisms were distinctly superior to those of PIPC.4. Side effects occurred in 10% (10/96) of the TAZ/PIPC group and 7% (7/95) of the PIPC group. Abnormal clinical laboratory test values were observed in 22% (20/92) of the TAZ/PIPC group and 18% (17/93) of the PIPC group. Thus, there were no significant differences between the two administration groups.5. The usefulness rate in the TAZ/PIPC group was 87% (75/86) and it was 85% (67/79) in the PIPC group, showing no significant difference between them.The results suggest that TAZ/PIPC administered at a dose of 2.5 g (titer) twice a day is more useful than PIPC administered at a dose of 2.0g (titer) twice a day in the treatment of bacterial pneumonia.